<DOC>
	<DOCNO>NCT00742027</DOCNO>
	<brief_summary>This study evaluate efficacy oral panobinostat patient refractory/relapsed classical HL receive prior treatment high dose chemotherapy autologous stem cell transplant . Safety panobinostat also assess . Other marker may correlate efficacy safety explore .</brief_summary>
	<brief_title>Phase II Study Oral Panobinostat Adult Patients With Relapsed/Refractory Classical Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Patient age ≥ 18 year 2 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 3 . Patient history classical HL ( i.e . Nodular sclerosing , Mixedcellularity , Lymphocyterich , Lymphocyte deplete ) 4 . Patient progressive disease receive high dose chemotherapy AHSCT Note : If last therapy ≥ 18 month ago , biopsy perform confirm diagnosis . Note : Patient receive ≤5 prior systemic treatment regimen ( See Posttext supplement 2 definition example ) Note : Patients allow study also receive allogeneic hematopoietic stem cell transplant , however therapy alone sufficient inclusion study . 5 . Patient least one site measurable nodal disease baseline ≥ 2.0 cm long transverse diameter clearly measurable least two perpendicular dimension , determine CT scan ( MRI allow CT scan perform ) . Note : Patients bone marrow involvement eligible , criterion alone use disease measurement 6 . Patient follow laboratory value ( lab may repeat , need , obtain acceptable value screen fail ) : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10 9/L [ SI unit 1.5 x 109/L ] Platelet count ≥ 75 x 109/L Serum potassium , magnesium , phosphorus , sodium , total calcium ( correct serum albumin ) ionize calcium within normal limit ( WNL ) institution Note : Potassium , calcium , magnesium , sodium , and/or phosphorus supplement may give correct value &lt; LLN . Postcorrection value must deem clinically significant abnormality prior patient dose . Serum creatinine ≤ 1.5 x ULN Serum bilirubin ≤ 1.5 x ULN ( ≤ 3.0 x ULN , patient Gilbert syndrome ) AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN ≤ 5.0 x ULN transaminase elevation due disease involvement 7 . Clinically euthyroid Note : Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . 8 . Written inform consent obtain patient prior studyspecific screening procedure 9 . Patient ability swallow capsule tablets 1 . Patient history prior treatment DAC inhibitor include panobinostat 2 . Patient need valproic acid medical condition study within 5 day prior first panobinostat treatment 3 . Patient treat monoclonal antibody therapy ( e.g. , rituximab anti CD30 antibody , etc . ) within 4 week start study treatment 4 . Patient receive chemotherapy investigational drug undergone major surgery ≤ 2 week prior start study drug whose side effect therapy resolve ≤ grade 1 5 . Patient treat &gt; 5 prior systemic line treatment ( see Posttext supplement 2 definition example ) 6 . Patient receive prior radiation therapy ≤ 4 week limited field radiotherapy ≤ 2 week prior start study treatment whose side effect therapy resolve ≤ grade 1 7 . Patient use anticancer therapy concomitantly 8 . Patient treat allogeneic hematopoietic stem cell transplant currently receive immunosuppressive therapy within 90 day prior start screen and/or ≥ Grade 2 graft versus host disease ( GvHD ) 9 . Patient history another primary malignancy ≤ 3 year study entry , exception nonmelanoma skin cancer , carcinoma situ uterine cervix 10 . Patient history CNS involvement lymphoma 11 . Patient impaired cardiac function include follow : Complete leave bundle branch block use permanent cardiac pacemaker , congenital long QT syndrome , history presence ventricular tachyarrhythmias , clinically significant rest bradycardia ( &lt; 50 beat per minute ) , QTcF &gt; 450 msec screen ECG , right bundle branch block + leave anterior hemiblock ( bifascicular block ) Presence atrial fibrillation ( ventricular heart rate &gt; 100 bpm ) Previous history angina pectoris acute MI within 6 month Congestive heart failure ( New York Heart Association functional classification IIIIV ) baseline MUGA/Echo show LVEF &lt; 45 % 12 . Patient clinically significant heart disease ( e.g. , uncontrolled hypertension ) 13 . Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , obstruction , stomach and/or small bowel resection ) 14 . Patient unresolved diarrhea ≥ grade 2 15 . Patient concurrent severe and/or uncontrolled medical condition ( ) ( e.g. , uncontrolled diabetes mellitus , active uncontrolled infection , chronic obstructive chronic restrictive pulmonary disease include dyspnoea rest cause ) could cause unacceptable safety risk compromise compliance protocol 16 . Patient known history HIV seropositivity ( screen HIV test require ) 17 . Patient use medication relative risk prolong QT interval induce Torsade de Pointes , treatment discontinue switched different medication prior start study drug 18 . Patient woman pregnant breast feeding , woman childbearing potential ( WOCBP ) willing use double method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . WOCBP must negative serum pregnancy test baseline . 19 . Male patient whose sexual partner ( ) WOCBP willing use double method contraception , one include condom , study 3 month end treatment . Patients follow contraindication PET exclude [ 18F ] FDG PET study ( applicable center participate PET study ) : 20 . Fasting blood glucose 200 mg/dL , time PET scan 21 . Inability lay 60 minute history claustrophobia 22 . Patient participate center Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Classical Hodgkin Lymphoma</keyword>
	<keyword>Classical Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Nodular sclerosing</keyword>
	<keyword>Mixed-cellularity</keyword>
	<keyword>Lymphocyte-rich</keyword>
	<keyword>Lymphocyte deplete</keyword>
	<keyword>HL</keyword>
	<keyword>Classical HL</keyword>
	<keyword>Refractory Hodgkin 's Lymphoma</keyword>
	<keyword>Refractory Hodgkin Lymphoma</keyword>
	<keyword>Refractory HL</keyword>
</DOC>